Related Experiment Videos
Abuse liability of bretazenil and other partial agonists
E M Sellers1, H L Kaplan, U E Busto
1Clinical Research and Treatment Institute, Addition Research Foundation, Toronto, Ontario, Canada.
Clinical Neuropharmacology
|January 1, 1992
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Psilocybin: Good Trip or Bad Trip.
Clinical pharmacology and therapeutics·2017
Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.
The Journal of pharmacology and experimental therapeutics·2016
Deconstructing Designer Drugs.
Clinical pharmacology and therapeutics·2016
The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Clinical pharmacology and therapeutics·2016
Update on tamper-resistant drug formulations.
Drug and alcohol dependence·2013
Cognitive toxicity of drugs used in the elderly.
Dialogues in clinical neuroscience·2011
Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.
Clinical neuropharmacology·2026
Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.
Clinical neuropharmacology·2026
A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.
Clinical neuropharmacology·2026
Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.
Clinical neuropharmacology·2026
Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.
Clinical neuropharmacology·2026
Self-Reported Adverse Events in Psychiatric Outpatients Taking Hypnotics: Higher Real-World Frequencies Than Those Listed in Package Inserts.
Neuropsychopharmacology reports·2026